New crown "special effects drug" (hydroxy) chloroquine side effects? FDA emergency authorization condemned!

On March 28, local time, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the treatment of COVID-19 inpatients.
a number of multinational drug companies have donated chloroquine or hydroxychloroquine to the world, such as Novartis, which has pledged to donate up to 130 million hydroxyquins and Bayer, which has donated 3 million tablets of chloroquine to the United States.
but there has been growing recent questioning of chloroquine and hydroxychloroquine, with former FDA leaders condemning the FDA's emergency authorization for malaria drugs, Science reported.
in Sweden, several hospitals have reportedly stopped treating COVID-19 patients with chloroquine.
severe side effects, with several Swedish hospitals suspending (hydroxy) chloroquine, and a Patient in Stockholm, Carl Sydenhag, who was diagnosed with COVID-19 on March 23, and doctors later took two tablets of chloroquine a day.
but after taking chloroquine, patients experience severe side effects such as cramping, vision loss, headache, etc. "Three weeks ago, Salgrenska University Hospital stopped using chloroquine for COVID-19, after reports that the side effects of chloroquine were more severe than expected, particularly in the heart, and there was no strong evidence that chloroquine could treat COVID-19," said Magnus Gissl?n, chief physician in the infection department at Salgrenska University Hospital in
.
" FDA emergency authorization is condemned According to Sicence reports, the FDA's former leadership said that the two recent emergency use authorizations (EUA) for the treatment of COVID-19 malaria drugs are based on weak clinical evidence that has jeopardized the true value of studying the drug COVID-19, and that the March 28 emergency authorization to use chlorophyll phosphate and oxysulphyre sulphate undermines the FDA's scientific authority because the authorization is not based on scientific evidence. Margaret Hamburg, a former
FDA commissioner, said: "We understand the desire to find an early treatment for COVID-19, but more evidence is needed to prove the effectiveness of the drug before encouraging widespread use, and valuable clinical data on antimalarial drug treatment COVID-19 could have been collected within weeks, but emergency use authorizations make it more difficult to collect valid data."
" remdesivir, first known as the "God Drug," was also the first drug to begin clinical trials in The U.S. to treat COVID-19, but because of Trump's madness, antimalarial drugs in the U.S. "fire" have somewhat hampered Redsivir's clinical trials. David Boulware, an infectious disease researcher at the University of Minnesota at the university of
, said: "Several colleagues involved in the Redsewe treatment COVID-19 clinical trial said they had encountered a number of patients with COVID-19 who opted out of the remdesivir study and requested to take hydroxychloroquine.
"the FDA's emergency authorization has discouraged patients from enrolling in clinical trials."
CDC Guidelines for the Removal of Chloroquine and Hydroxychloroquine, the U.S. Centers for Disease Control and Prevention (CDC) has just removed the key dose information for the new coronal pneumonia drug chloroquine and hydroxychloroquine, published three days ago from its website, under the title "Clinician's guidelines on treatment options for patients with new coronary pneumonia."
the guidelines guide doctors on the prescribing methods of hydroxychloroquine and chloroquine, it is worth noting that the guidelines initially stated that "although the best dose and effectiveness of hydroxychloroquine for the treatment of new coronal pneumonia is not clear, some clinicians have reported on the method of prescribing the drug".
the guidelines were published, many medical experts were surprised by the recommendation that doctors could use them to patients without yet having their effects yet. Lynn Goldman, dean of the Milken School of Public Health at George Washington University in
, said: "Why does the CDC publish unscientificly proven drug information? It doesn't make sense, it's unusual.
" hydroxychloroquine, azithromycin joint treatment paper deleted March 20, French scientist Didier published in the International Journal of Antimicrobial Agents, said that the effects of hydroxychloroquine, azithromycin combined treatment.
just two weeks later, the International Society for The Biochemistry of Antimicrobials (ISAC) published an open letter on its official website saying it withdrew its paper because the results of non-randomized clinical trials for the treatment of new crown pneumonia by hydroxychloroquine and azithromycin did not meet the industry consensus criteria.
the effectiveness of the antimalarial drugs chloroquine and hydroxychloroquine in the treatment of COVID-19 requires a wealth of scientifically effective clinical data.
, in addition, Redsewe's clinical study will be completed in the near future, can it become the first clinical trial to prove effective treatment of COVID-19 drugs? We'll see.
Reference Source: 1, SOME SWEDISH HOSPITALS HAVE STOPPED USING CHLOROQUINE TO TREAT COVID-19 AFTER REPORTS OF SEVERE EFFECTS SIDES 2, Former FDA leaders decry decry oedd by malaria drugs for coronavirus 3, hydroxychloroquine medication guidelines removed by the U.S. CDC's official website, Trump claims his new crown drug.